The impact of ER levels on the response to tamoxifen was evaluated in 1,623 postmenopausal primary breast cancer patients treated at our center (median follow-up 8.2 years). In patients receiving adjuvant tamoxifen a significantly longer disease-free survival (DFS) was observed when ER levels were elevated (p<0.00001). Very high ER (>424 fmol/mg protein) appeared to be detrimental in node-negative patients not treated with tamoxifen.
OsborneC.K., ElledgeR.M., FuquaS.A.W.Estrogen receptors in breast cancer therapy.Sci Am Sci Med1996; 3: 32–41.
2.
ElledgeM.E., OsborneC.K.Oestrogen receptors and breast cancer.BMJ1997; 314: 1843–44.
3.
HeusonJ.C., LongevalE., MattheiemW.H., DeboelM.C., SylvesterR.J., LeclercqG.Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer.Cancer1977; 39: 1971–7.
4.
ThorpeS.M., ChristensenI.B.J., RasmussenB.B., RoseC.Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer.Eur J Cancer1993; 29A: 971–7.
5.
Sancho-GarnierH., DelarueJ.C., MouriesseH.Is the negative prognostic value of high oestrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product?Eur J Cancer1995; 31A(11): 1851–5.
6.
Early Breast Cancer Trialists’ Group.Tamoxifen for early breast cancer: an overview of the randomized trials.Lancet1998; 351: 1451–67.
7.
AllredD.C., HarveyJ.M., BerardoM., ClarkG.Prognostic and predictive factors in breast cancer by immunohistochemical analysis.Mod Pathol1998; 11(2): 155–68.
